LifeMD Shares Tumble on Earnings Miss and GLP-1 Market Struggles
LifeMD stock plunged 25% after missing Q3 earnings and cutting guidance, citing fierce competition from low-cost compounded GLP-1 weight loss drugs despite Novo and Lilly partnerships.
/ 33 items
#HIMS↓
Citi Surprised by Hims Exclusion as Novo Cuts GLP-1 Prices
Citi analyst Daniel Grosslight says competition is increasing in weight-loss drug pricing after Novo Nordisk introduced a $199 monthly offer for Wegovy and Ozempic, leaving out Hims & Hers as a distribution partner.
LifeMD Offers Lowest Cash-Pay Price for Wegovy & Ozempic at $199/Month
LifeMD now provides the lowest nationwide cash-pay price for Wegovy and Ozempic at $199/month for new patients, supporting more affordable access to GLP-1 weight-loss treatments.
Hims & Hers Expands Into Lab Testing to Boost Preventive Care
Hims & Hers Health launches lab testing with Quest Diagnostics, offering affordable biomarker tests and personalized health plans as part of its preventive care expansion.
Trump Slashes Obesity Drug Prices with Lilly, Novo Nordisk Deals
President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.
Hims & Hers Shares Jump on Talks With Novo Nordisk, Strong Q3 Results
Hims & Hers Health rose in after-hours trading after revealing talks with Novo Nordisk about offering Wegovy’s new obesity pill. The telehealth firm also beat Q3 revenue estimates, reporting nearly $600 million in sales and strong subscriber growth.